伦敦和纽约——Compass Pathways plc（纳斯达克：CMPS）于周三公布了第一季度业绩，各项指标均超出分析师预期。 受业绩超预期及监管进展重大利好双重驱动，该生物科技公司股价在盘前交易中大涨7.90%。 公司调整后每股亏损为$0.30，优于市场普遍预期的每股亏损$0.43。与此同时，公司旗下用于治疗难治性抑郁症的COMP360裸盖菇素疗法正稳步推进监管审批流程。 美国食品药品监督管理 ...

Shares of Compass Pathways (NASDAQ:CMPS) climbed nearly 8% in premarket trading on Wednesday after the company reported first ...

Compass Pathways Plc（指南针疗法）近日股价触及52周高点$10.22，创下重要里程碑。过去一年，该股累计涨幅高达140%，充分彰显了公司强劲的成长势头。这家专注于心理健康领域的生物科技公司目前市值达13.1亿美元，不过InvestingPro的分析显示，该股目前交易价格已高于其公允价值，跻身心理健康板块中估值偏高的股票之列。股价的大幅攀升反映出投资者对Compass Pathw ...

Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based ...

Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed ...

COMPASS Pathways Plc CMPS reported first-quarter earnings on Wednesday before the market open. Here’s a rundown of the report ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

Compass Pathways stock jumped Wednesday after the psychedelics-tied biotech significantly boosted its cash holdings.

Compass Pathways is set to start its biggest clinical trial yet by the end of this year. It will study whether synthetic psilocybin can help people with treatment-resistant depression. Compass' new ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards ...